Chu Chen

Papers

Total Citations

H-Index

About

Chu Chen is a distinguished researcher whose work has significantly advanced the field of pharmacogenomics, with a particular focus on the genetic determinants of drug metabolism and disease susceptibility. Dr. Chen’s key research areas include molecular epidemiology, cancer genetics, and the development of high-throughput genotyping technologies. A major contribution is the adaptation of the oligonucleotide ligation assay (OLA) for genotyping the human *NAT2* gene, a critical enzyme in the metabolism of arylamine carcinogens and numerous drugs. This seminal work, published in 1997, provided an accurate, efficient, and reliable method for determining acetylator genotype, enabling large-scale studies on the link between *NAT2* polymorphisms and bladder cancer risk. By pioneering the use of 96-well microplates and robotic workstations, Dr. Chen’s assay dramatically increased sample throughput, laying the groundwork for modern high-throughput genotyping platforms. This foundational contribution has been cited over 20 times and remains a cornerstone in the field, demonstrating Dr. Chen’s lasting impact on personalized medicine and public health.